We previously reported mother-to-child transmission of HIV-1 in nine (6.7%) of 135 children on nevirapine prophylaxis in Vietnam. In the current study, we investigated the appearance and profile of antiretroviral drug (ARV) resistance mutations, the predicted coreceptor usage, and the genetic diversity of HIV-1 strains isolated from the eight pairs of HIV-1-infected mothers and their children, who were followed up to 12 months after birth. Portions of the pol and env C2V3 regions of the HIV-1 strains were analyzed genetically. HIV-1 CRF01_AE RNA was detected in four (50%) children at delivery. Y181C, a nevirapine resistance mutation, appeared in two (25%) children 1 and 3 months after birth, respectively. No ARV resistance mutation was detected in the mothers, though three mothers were on ARV prophylaxis. Five mothers and their children harbored CCR5-tropic (R5) viruses. Two mothers harbored both R5 and CXCR4-tropic (X4) viruses, but their children harbored only R5 viruses even though the X4 viruses were dominant in the mothers. In the remaining one mother, HIV-1 RNA was not amplified and her child harbored both R5 and X4 viruses at birth, but only X4 virus 12 months after delivery. The infants' viruses were more homogeneous than their mothers' viruses (mean distance: 0.5% vs. 1.1%, respectively). This is the first molecular epidemiological study of vertical HIV-1 infections in Vietnam. These findings may provide useful knowledge for the prevention of mother-to-child transmission of HIV-1 and the antiretroviral treatment of children in Vietnam.
Get full access to this article
View all access options for this article.
References
1.
UNAIDS/WHO: Global report: UNAIDS report on the global AIDS epidemic 2012. UNAIDS 2012. www.unaidstoday.org.
2.
The Working Group on Mother-To-Child Transmission of HIV: Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: Results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol, 1995; 8(5):506–510.
3.
European Collaborative Study: Risk factors for mother-to-child transmission of HIV-1. Lancet, 1992; 339(8800):1007–1012.
4.
CoovadianHM, RollinsNC, BlandRM, et al.: Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: An intervention cohort study. Lancet, 2007; 369(9567):1107–1116.
5.
JohnGC and KreissJ: Mother-to-child transmission of human immunodeficiency virus type 1. Epidemiol Rev, 1996; 18(2):149–157.
6.
KourtisAP, LeeFK, AbramEJ, et al.: Mother to child transmission of HIV-1: Timing and implications for prevention. Lancet Infect Dis, 2006; 6(11):726–732.
7.
DengH, LiuR, EllmeierW, et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature, 1996; 381(6584):661–666.
8.
BergerEA, DomsRW, FenyoEM, et al.: A new classification for HIV-1. Nature, 1998; 391(6664):240.
9.
CasperCH, ClevestigP, CarlenorE, et al.: Link between the X4 phenotype in human immunodeficiency virus type 1-infected mothers and their children, despite the early presence of R5 in the child. J Infect Dis, 2002; 186(7):914–921.
10.
NyamacheAK, MuigaiAW, Ng'ang'aZ, and KhamadiSA: Profile of HIV type 1 coreceptor tropism among Kenyan patients from 2009 to 2010. AIDS Res Hum Retroviruses, 2013; 29(8):1105–1109.
11.
SalvatoriF and ScarlattiG: HIV type 1 chemokine receptor usage in mother-to-child transmission. AIDS Res Hum Retroviruses, 2001; 17(10):925–935.
12.
ScarlattiG, HodaraV, RossiP, et al.: Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. Virology, 1993; 197(2):624–629.
13.
MofensonLM and MunderiP: Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J Acquir Immune Defic Syndr, 2002; 30(2):200–215.
14.
NewellML and ThorneC: Antiretroviral therapy and mother-to-child transmission of HIV-1. Expert Rev Anti Infect Ther, 2004; 2(5):717–732.
15.
JacksonJB, MusokeP, FlemingT, et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet, 2003; 362(9387):859–868.
16.
EshlemanSH, MracnaM, GuayLA, et al.: Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS, 2001; 15(15):1951–1957.
17.
UNAIDS/WHO: AIDS epidemic update. UNAIDS 2007. http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf.2007.
18.
NguyenTA, OosterhoffP, NgocYP, et al.: Barriers to access prevention of mother-to-child transmission for HIV positive women in a well-resourced setting in Vietnam. AIDS Res Ther, 2008; 5(7):1–12.
19.
Ministry of Health, Viet Nam administration of HIV/AIDS control: Viet Nam HIV/AIDS estimates and projections 2007–2012. Ha Noi, 2009.
20.
Ministry of Health, Socialist Republic of Viet Nam: Guidelines for Diagnosis and Treatment of HIV/AIDS. 2005 (No. 06/2005/QD-BYT).
21.
Viet Nam National Committee for AIDS, Drugs and Prostitution Prevention and Control: Viet Nam AIDS Response Progress Report 2012. Following Up the 2011 Political Declaration on HIV/AIDS. Ha Noi, 2012. www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_VN_Narrative_Report.pdf.
22.
HaTT, AnhNM, BaoNH, et al.: HIV-1 mother-to-child transmission, post-test counselling, and antiretroviral prophylaxis in Northern Viet Nam: A prospective observational study. Scand J Infect Dis, 2012; 44(11):866–873.
23.
LihanaRW, LwembeRM, BiX, et al.: Efficient monitoring of HIV-1 vertically-infected children in Kenya on first-line antiretroviral therapy. J Clin Virol, 2011; 52(2):123–128.
24.
IshizakiA, CuongNH, ThucPV, et al.: Profile of HIV type 1 infection and genotypic resistance mutations antiretroviral drugs in treatment-naive HIV type 1-infected individuals in Hai Phong, Viet Nam. AIDS Res Hum Retroviruses, 2009; 25(2):175–182.
25.
PhanTTC, IshizakiA, PhungDC, et al.: Characterization of HIV type 1 genotypes and drug resistance mutations among drug-naive HIV type 1-infected patients in Northern Vietnam. AIDS Res Hum Retroviruses, 2010; 26(2):233–235.
26.
MildM, BjörndalA, MedstrandP, and FenyöEM: Isolation of human immunodeficiency virus-type 1 (HIV-1) clones with biological and molecular properties of the primary isolate. Virology, 2006; 350(1):58–66.
27.
NdembiN, YumoH, TakehisaJ, et al.: HIV type 1 infection in Pygmy hunter gatherers is from contact with Bantu rather than from nonhuman primates. AIDS Res Hum Retroviruses, 2003; 19(5):435–439.
28.
HIV Drug Resistance Database, Stanford University. February2014. http://hivdb.stanford.edu/pages/algs/HIVdb.html.
29.
WensingAM, CalvezV, GunthardHF, et al.: 2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med, 2014; 22(3):642–650.
30.
LwembeR, LihanaRW, OchiengW, et al.: Changes in the HIV type 1 envelope gene from non-subtype B HIV type 1-infected children in Kenya. AIDS Res Hum Retroviruses, 2009; 25(2):141–147.
31.
NowakP, KarlssonAC, NaverL, et al.: The selection and evolution of viral quasispecies in HIV-1 infected children. HIV Med, 2002; 3(1):1–11.
32.
PersaudD, BedriA, ZiemniakC, et al.: Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission. AIDS Res Hum Retroviruses, 2011; 27(8):823–829.
33.
ArrivéE, NewellML, EkoueviDK, et al.: Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: A meta-analysis. Int J Epidemiol, 2007; 36(5):1009–1012.
34.
StringerJS, McConnellMS, KiarieJ, et al.: Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: A multi-country, prospective cohort study. PLoS Med, 2010; 7(2):1–13.
35.
MoorthyA, GuptaA, BhosalaR, et al.: Nevirapine resistance and breast-milk HIV transmission: Effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS One, 2009; 4(1):1–8.
36.
Wind-RotoloM, DurandC, CranmerL, et al.: Identification of nevirapine-resistance HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis, 2009; 199(9):1301–1309.
37.
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. June2013. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.
38.
CavarelliM, KarissonI, ZanchettaM, et al.: HIV-1 with multiple CCR5/CXCR4 chimeric receptor use is predictive of immunological failure in infected children. PLoS One, 2008; 3(9):e3292.
39.
SalvatoriF and ScarlattiG: HIV type 1 chemokine receptor usage in mother-to-child transmission. AIDS Res Hum Retroviruses, 2001; 17(10):925–935.
40.
HuangW, EshlemanSH, TomaJ, et al.: Vertical transmission of X4 tropic and dual tropic HIV-1 in five Ugandan mother-infant pairs. AIDS, 2009; 23(14):1903–1908.
41.
WadeCM, LobidelD, and BrownAJ: Analysis of human immunodeficiency virus type 1 env and gag sequence variants derived from a mother and two vertically infected children provides evidence for the transmission of multiple sequence variants. J Gen Virol, 1998; 79(5):1055–1068.
42.
WolinskySM, WikeCM, KorberBT, et al.: Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science, 1992; 255(5048):1134–1137.
43.
DickoverRE, GarrattyEM, PlaegerS, and BrysonYJ: Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum. J Virol, 2001; 75(5):2194–2203.
44.
ScarlattiG, LeitnerT, HalapiE, et al.: Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. Proc Natl Acad Sci USA, 1993; 90(5):1721–1725.
45.
VerhofstedeC, DemecheleerE, De CabooterN, et al.: Diversity of the human immunodeficiency virus type 1 (HIV-1) env sequence after vertical transmission in mother-child pairs infected with HIV-1 subtype A. J Virol, 2003; 77(5):3050–3057.
46.
AhmadN, BaroudyBM, BakerRC, and ChappeyC: Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mother and infants after perinatal transmission. J Virol, 1995; 69(2):1001–1012.
47.
PersaudD, PiersonT, RuffC, et al.: A stable latent reservoir for HIV-1 in resting CD4 (+) T lymphocytes in infected children. J Clin Invest, 2000; 105(7):955–1003.
48.
CeballosA, AndreaniG, RipamontiC, et al.: Lack of viral selection in human immunodeficiency virus type 1 mother-to-child transmission with primary infection during late pregnancy and/or breastfeeding. J Gen Virol, 2008; 89(11):2773–2782.
